U.S. flag An official website of the United States government
  1. Home
  2. News & Events
  3. Regenerative Medicine 101 Webinar: Information for Patients, Caregivers & Advocates - 11/16/2021 - 11/16/2021
  1. News & Events

Public

Event Title
Regenerative Medicine 101 Webinar: Information for Patients, Caregivers & Advocates
November 16, 2021


Date:
November 16, 2021
Time:
11:00 AM - 12:00 PM ET

The FDA’s Center for Biologics Evaluation and Research (CBER) Office of Tissues and Advanced Therapies (OTAT) is hosting a public webinar on Tuesday, November 16, 11:00 a.m.-12:00 p.m. ET. 

The webinar will bring together patients, caregivers, advocates, and other important stakeholders to discuss how the FDA is working to advance regenerative medicine and its role in ensuring regenerative medicine treatments, such as approved gene therapies, are safe and effective for patients. The webinar speakers will be Wilson Bryan, MD, Director of OTAT, and Anne Rowzee, PhD, Associate Director of Policy for OTAT.

This webinar is the first in an educational webinar series called RegenMedEd: An FDA CBER OTAT Webinar Series on Regenerative Medicine. To register for the webinar, please visit: https://web.cvent.com/event/37570041-7a5f-4022-af80-d0401247fc3a/summary 

Promotional graphic for regenerative medicine 101 webinar hosted by the U.S. Food and Drug Administration. Image includes blue DNA helix.

Meeting Information & Registration

  • Date: Tuesday, November 16, 2021
  • Time: 11:00 a.m.–12:00 p.m. ET
  • Location: The webinar will be held via Zoom.
  • Registration: Registration is required to attend the webinar. Please register for the webinar now
  • Get Involved: Use the hashtag #RegenMedEd on Twitter to share a question in advance!

About the RegenMedEd Webinar Series

Regenerative medicine therapies, such as cell and gene therapies, hold promise for transforming medicine and creating options for patients living with difficult, rare, and often incurable diseases. Several approved regenerative medicine products are currently available, and research into regenerative medicine therapies in the United States continues rapidly, with many new therapies under investigation advancing into clinical studies. The FDA plays a vital role in facilitating the development of regenerative medicine therapies, as well as in ensuring approved products are safe and effective for patients.

To further engage patients, caregivers, and advocates on the topic of regenerative medicine, OTAT is excited to present an educational webinar series called RegenMedEd: An FDA CBER OTAT Webinar Series on Regenerative Medicine. The RegenMedEd webinar series aims to bring together patients, caregivers, patient advocates, and FDA staff to discuss foundational information about regenerative medicine therapies, such as gene therapy and cell therapy, and explore opportunities for stakeholders to engage with the FDA to help advance drug development.

Back to Top